Evaluation of [¹⁸F]Favipiravir in Rodents and Nonhuman Primates (NHP) with Positron Emission Tomography.

ABSTRACT: The COVID-19 pandemic has posed a significant challenge to global public health. In response, the search for specific antiviral drugs that can effectively treat the disease caused by the SARS-CoV-2 virus has become a priority. While significant progress has been made in this regard, much work remains to address this ongoing crisis effectively. Favipiravir is an antiviral drug initially developed for the treatment of influenza and has received approval for emergency use for COVID-19 in many countries. A better understanding of the biodistribution and pharmacokinetics of Favipiravir in vivo would facilitate the development and translation of clinical antiviral drugs for COVID-19. Herein, we report the evaluation of [¹⁸F]Favipiravir in naive mice, transgenic mice models of Alzheime

SUBMITTER: Rong J 

PROVIDER: S-EPMC10146102 | biostudies-literature | 2023 Mar

REPOSITORIES: biostudies-literature